Non-Viral Drug Delivery Systems Market: Size, Growth, and Strategic Insights
Author : kajal patil | Published On : 09 Jun 2026
The non-viral drug delivery systems industry is witnessing accelerated innovation and adoption, driven by the need for safer, more efficient therapeutic delivery alternatives. Advances in biomaterials and formulation technologies are expanding the industry size and opening diverse market opportunities globally.
Market Size and Overview
The Non-Viral Drug Delivery Systems Market is estimated to be valued at USD 9.23 Bn in 2025 and is expected to reach USD 23.10 Bn by 2032, growing at a compound annual growth rate (CAGR) of 14.00% from 2025 to 2032.
This market growth is underpinned by rising demand for gene therapy and mRNA-based vaccines, as well as an increasing preference for non-viral vectors due to safety concerns linked with viral delivery. The market report highlights evolving market segments including lipid nanoparticles, polymeric nanoparticles, and inorganic nanoparticles, all contributing to expanding market revenue and industry share.
Market Drivers
- Rising Demand for Safer Gene Delivery Platforms: A key market driver is the growing focus on developing safer and less immunogenic alternatives to viral vectors. For instance, in 2024, Arcturus Therapeutics successfully advanced its LUNAR lipid nanoparticle platform in clinical trials for mRNA therapeutics, showcasing superior safety profile and efficiency. This validation by leading companies underscores the rising market growth and increasing market demand for non-viral drug delivery systems, reflecting promising Non-Viral Drug Delivery Systems Market Trends projected in the market forecast.
PEST Analysis
- Political: Governments worldwide, particularly in North America and Europe, have increased funding for gene and RNA therapies in 2024, encouraging regulatory frameworks that facilitate quicker approvals for non-viral delivery technologies.
- Economic: Despite global economic uncertainties in early 2025, investments in biotech innovation increased by 12%, driven by growing healthcare expenditure and venture capital influx into drug delivery startups.
- Social: Increasing patient awareness and preference for minimally invasive treatment methods has boosted acceptance and uptake of non-viral drug delivery solutions, as evidenced by growing prescription rates in developed markets in 2024.
- Technological: Breakthroughs in nanoparticle engineering and targeted delivery technologies in 2025, including developments by companies such as CureVac and Entos Pharmaceuticals, have enhanced delivery efficiency and therapeutic index, positively impacting market dynamics and business growth.
Promotion and Marketing Initiatives
Promotional strategies increasingly focus on demonstrating clinical efficacy and safety data to healthcare professionals and stakeholders. A notable marketing initiative in 2024 was Bio-Path Holdings’ partnership with leading oncology centers to showcase their novel siRNA non-viral delivery platform in real-world settings. This strategy effectively elevated market visibility and investor confidence, directly contributing to enhanced market share and revenue growth through expanded market penetration.
Key Players
- Arcturus Therapeutics
- Bio-Path Holdings
- CureVac
- Entos Pharmaceuticals
- The RNA Immunotherapies
Recent strategies include:
- In 2025, Arcturus Therapeutics expanded its manufacturing capacity to meet global demand surge, leading to a 20% increase in annual revenue.
- CureVac launched an innovative lipid nanoparticle platform for next-gen mRNA vaccine delivery in 2024, significantly broadening its market scope and business growth.
- Bio-Path Holdings entered a strategic partnership in 2025 with a major pharmaceutical to co-develop non-viral siRNA delivery therapies, accelerating product pipeline development.
- Entos Pharmaceuticals secured major funding in 2024 to scale up clinical trials of its Fusogenix delivery system, fueling market expansion opportunities.
- The RNA Immunotherapies company focused on optimizing delivery vectors, boosting its industry share by targeting rare genetic disorders with precision therapies.
FAQs
1. Who are the dominant players in the Non-Viral Drug Delivery Systems market?
Dominant players include Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, and The RNA Immunotherapies, all of whom have made significant advancements in delivery platforms and market expansion throughout 2024 and 2025.
2. What will be the size of the Non-Viral Drug Delivery Systems market in the coming years?
The market size is expected to grow from USD 9.23 billion in 2026 to USD 23.10 billion by 2033, reflecting a strong CAGR of 14%, driven by increasing adoption of safer and more efficient drug delivery systems.
3. Which drug delivery segments show the largest growth opportunity?
Lipid nanoparticles and polymeric nanoparticle segments represent the largest growth opportunities, owing to their enhanced biocompatibility and targeting efficiencies as confirmed by recent clinical and commercial developments.
4. How will market development trends evolve over the next five years?
Market development trends will likely emphasize non-viral delivery platforms with improved safety profiles and scalability, supported by rising investments in RNA therapeutics and expanding collaborative efforts between biotech firms and healthcare institutions.
5. What is the competitive landscape and challenges in the Non-Viral Drug Delivery Systems market?
The competitive landscape is marked by innovation-driven market players focusing on technology enhancement and strategic partnerships. However, challenges include regulatory hurdles, scalability issues, and high R&D costs which require sustained investment and innovation.
6. What go-to-market strategies are commonly adopted in the Non-Viral Drug Delivery Systems market?
Common strategies include clinical data-driven marketing, partnerships with leading medical centers, manufacturing capacity expansions, and co-development agreements aimed at accelerating product commercialization and enhancing market penetration.
Get more insights on - Non-Viral Drug Delivery Systems Market
Get this Report in Japanese Language: 非ウイルス性薬物送達システム市場
Get this Report in Korean Language: 비바이러스약물전달시스템시장
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
